165 related articles for article (PubMed ID: 28789648)
21. [Costs of healthcare resource consumption after a myocardial infarction in France: An estimate from a medicoadministrative database (GSB)].
Philippe F; Blin P; Bouée S; Laurendeau C; Torreton E; Gourmelin J; Velkovski-Rouyer M; Levy-Bachelot L; Steg G
Ann Cardiol Angeiol (Paris); 2017 Apr; 66(2):74-80. PubMed ID: 28139200
[TBL] [Abstract][Full Text] [Related]
22. Economic burden of advanced melanoma in France, Germany and the UK: a retrospective observational study (Melanoma Burden-of-Illness Study).
Grange F; Mohr P; Harries M; Ehness R; Benjamin L; Siakpere O; Barth J; Stapelkamp C; Pfersch S; McLeod LD; Kaye JA; Wolowacz S; Kontoudis I
Melanoma Res; 2017 Dec; 27(6):607-618. PubMed ID: 28800027
[TBL] [Abstract][Full Text] [Related]
23. Pharmacoeconomic assessment of specific immunotherapy versus current symptomatic treatment for allergic rhinitis and asthma in France.
Omnes LF; Bousquet J; Scheinmann P; Neukirch F; Jasso-Mosqueda G; Chicoye A; Champion L; Fadel R
Eur Ann Allergy Clin Immunol; 2007 May; 39(5):148-56. PubMed ID: 17626329
[TBL] [Abstract][Full Text] [Related]
24. Burden of herpes zoster: the direct and comorbidity costs of herpes zoster events in hospitalized patients over 50 years in France.
Blein C; Gavazzi G; Paccalin M; Baptiste C; Berrut G; Vainchtock A
BMC Infect Dis; 2015 Aug; 15():350. PubMed ID: 26286598
[TBL] [Abstract][Full Text] [Related]
25. Confirming the timing of phase-based costing in oncology studies: a case example in advanced melanoma.
Atkins M; Coutinho AD; Nunna S; Gupte-Singh K; Eaddy M
J Med Econ; 2018 Feb; 21(2):212-217. PubMed ID: 29022427
[TBL] [Abstract][Full Text] [Related]
26. Use Patterns and Costs of Isolated Limb Perfusion and Infusion in the Treatment of Regional Metastatic Melanoma: A Retrospective Database Analysis.
Ma Q; Zhao Z; Barber BL; Shilkrut M
Adv Ther; 2016 Feb; 33(2):282-9. PubMed ID: 26797898
[TBL] [Abstract][Full Text] [Related]
27. More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments.
Kandolf Sekulovic L; Peris K; Hauschild A; Stratigos A; Grob JJ; Nathan P; Dummer R; Forsea AM; Hoeller C; Gogas H; Demidov L; Lebbe C; Blank C; Olah J; Bastholt L; Herceg D; Neyns B; Vieira R; Hansson J; Rutkowski P; Krajsova I; Bylaite-Bucinskiene M; Zalaudek I; Maric-Brozic J; Babovic N; Banjin M; Putnik K; Weinlich G; Todorovic V; Kirov K; Ocvirk J; Zhukavets A; Kukushkina M; De La Cruz Merino L; Ymeri A; Risteski M; Garbe C
Eur J Cancer; 2017 Apr; 75():313-322. PubMed ID: 28264791
[TBL] [Abstract][Full Text] [Related]
28. Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting.
Toy EL; Vekeman F; Lewis MC; Oglesby AK; Duh MS
Curr Med Res Opin; 2015 Aug; 31(8):1561-72. PubMed ID: 26086578
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcomes and direct costs after transcatheter aortic valve implantation in French centres: a longitudinal study of 1332 patients using a national database.
Armoiry X; Obadia JF; Iung B; Polazzi S; Duclos A
Interact Cardiovasc Thorac Surg; 2016 Dec; 23(6):883-888. PubMed ID: 27600908
[TBL] [Abstract][Full Text] [Related]
30. Association between variations in the number of hospital beds and inpatient chemo/radiotherapy for breast cancer: a study using a large claim database.
Matsumoto HH; Ogiya R; Matsuda S
Acta Oncol; 2020 Sep; 59(9):1072-1078. PubMed ID: 32657192
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of financial burden following complications after major surgery in France: Potential return after perioperative goal-directed therapy.
Landais A; Morel M; Goldstein J; Loriau J; Fresnel A; Chevalier C; Rejasse G; Alfonsi P; Ecoffey C
Anaesth Crit Care Pain Med; 2017 Jun; 36(3):151-155. PubMed ID: 28096064
[TBL] [Abstract][Full Text] [Related]
32. Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages.
Alexandrescu DT
Dermatol Online J; 2009 Nov; 15(11):1. PubMed ID: 19951637
[TBL] [Abstract][Full Text] [Related]
33. Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries.
Vouk K; Benter U; Amonkar MM; Marocco A; Stapelkamp C; Pfersch S; Benjamin L
J Med Econ; 2016 Sep; 19(9):900-12. PubMed ID: 27123564
[TBL] [Abstract][Full Text] [Related]
34. [Bipolar I disorder in France: prevalence of manic episodes and hospitalisation-related costs].
de Zélicourt M; Dardennes R; Verdoux H; Gandhi G; Papatheodorou ML; Edgell ET; Khoshnood B; Chomette E; Even C; Fagnani F
Encephale; 2003; 29(3 Pt 1):248-53. PubMed ID: 12876549
[TBL] [Abstract][Full Text] [Related]
35. Estimated Healthcare Costs of Melanoma in Australia Over 3 Years Post-Diagnosis.
Elliott TM; Whiteman DC; Olsen CM; Gordon LG
Appl Health Econ Health Policy; 2017 Dec; 15(6):805-816. PubMed ID: 28756584
[TBL] [Abstract][Full Text] [Related]
36. Manic episodes: the direct cost of a three-month period following hospitalisation.
Olié JP; Lévy E
Eur Psychiatry; 2002 Sep; 17(5):278-86. PubMed ID: 12381498
[TBL] [Abstract][Full Text] [Related]
37. The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costs.
Reyes C; DaCosta Byfield S; Linke R; Satram-Hoang S; Teitelbaum AH
Melanoma Res; 2013 Apr; 23(2):159-66. PubMed ID: 23370422
[TBL] [Abstract][Full Text] [Related]
38. Outcomes following acute hospitalised myocardial infarction in France: An insurance claims database analysis.
Blin P; Philippe F; Bouée S; Laurendeau C; Torreton E; Gourmelin J; Leproust S; Levy-Bachelot L; Steg PG
Int J Cardiol; 2016 Sep; 219():387-93. PubMed ID: 27372604
[TBL] [Abstract][Full Text] [Related]
39. Frequency and Impact of Adverse Events in Inpatients: A Nationwide Analysis of Episodes between 2000 and 2015.
Sousa-Pinto B; Marques B; Lopes F; Freitas A
J Med Syst; 2018 Jan; 42(3):48. PubMed ID: 29374332
[TBL] [Abstract][Full Text] [Related]
40. Management and costs of treating lung cancer patients in a university hospital.
Dedes KJ; Szucs TD; Bodis S; Joerger M; Lowy A; Russi EW; Steinert HC; Weder W; Stahel RA
Pharmacoeconomics; 2004; 22(7):435-44. PubMed ID: 15137882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
